|
G |
Ano6 |
anoctamin 6 |
affects activity |
ISO |
Niflumic Acid affects the activity of ANO6 protein |
CTD |
PMID:24478309 |
|
NCBI chr 7:126,933,919...127,113,588
Ensembl chr 7:126,933,936...127,113,589
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
[Niflumic Acid co-treated with ciglitazone] results in increased activity of BAX protein; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased activity of BAX protein] |
CTD |
PMID:21067863 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Best1 |
bestrophin 1 |
decreases activity |
ISO |
Niflumic Acid results in decreased activity of BEST1 protein |
CTD |
PMID:19828819 |
|
NCBI chr 1:206,629,340...206,646,085
Ensembl chr 1:206,629,500...206,646,063
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of BID protein; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of BID protein] |
CTD |
PMID:21067863 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP3 protein; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP3 protein]; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP3 protein] |
CTD |
PMID:21067863 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases activity |
ISO |
benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [ciglitazone promotes the reaction [Niflumic Acid results in increased activity of CASP8 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Niflumic Acid promotes the reaction [ciglitazone results in increased activity of CASP8 protein]]; ciglitazone promotes the reaction [Niflumic Acid results in increased activity of CASP8 protein]; DDIT3 mutant form inhibits the reaction [ciglitazone promotes the reaction [Niflumic Acid results in increased activity of CASP8 protein]]; DDIT3 mutant form inhibits the reaction [Niflumic Acid promotes the reaction [ciglitazone results in increased activity of CASP8 protein]]; Niflumic Acid promotes the reaction [ciglitazone results in increased activity of CASP8 protein] |
CTD |
PMID:21067863 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP9 protein; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP9 protein]; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP9 protein] |
CTD |
PMID:21067863 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cftr |
CF transmembrane conductance regulator |
decreases activity |
ISO |
Niflumic Acid results in decreased activity of CFTR protein |
CTD |
PMID:14668136 |
|
NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756
|
|
G |
Cyp19a1 |
cytochrome P450, family 19, subfamily a, polypeptide 1 |
decreases activity decreases expression |
ISO |
Niflumic Acid results in decreased activity of CYP19A1 protein Niflumic Acid results in decreased expression of CYP19A1 mRNA |
CTD |
PMID:15964185 |
|
NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions increases expression |
ISO |
ciglitazone promotes the reaction [Niflumic Acid results in increased expression of DDIT3 protein]; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased activity of BAX protein]; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of BID protein]; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP3 protein]; DDIT3 mutant form inhibits the reaction [[Niflumic Acid co-treated with ciglitazone] results in increased cleavage of CASP9 protein]; DDIT3 mutant form inhibits the reaction [ciglitazone promotes the reaction [Niflumic Acid results in increased activity of CASP8 protein]]; DDIT3 mutant form inhibits the reaction [ciglitazone promotes the reaction [Niflumic Acid results in increased cleavage of PARP1 protein]]; DDIT3 mutant form inhibits the reaction [Niflumic Acid promotes the reaction [ciglitazone results in increased activity of CASP8 protein]]; DDIT3 mutant form inhibits the reaction [Niflumic Acid promotes the reaction [ciglitazone results in increased cleavage of PARP1 protein]]; DDIT3 results in increased susceptibility to [Niflumic Acid co-treated with ciglitazone]; Niflumic Acid promotes the reaction [ciglitazone results in increased expression of DDIT3 protein] |
CTD |
PMID:21067863 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Eif2a |
eukaryotic translation initiation factor 2A |
multiple interactions increases phosphorylation |
ISO |
ciglitazone promotes the reaction [Niflumic Acid results in increased phosphorylation of EIF2A protein]; Niflumic Acid promotes the reaction [ciglitazone results in increased phosphorylation of EIF2A protein] |
CTD |
PMID:21067863 |
|
NCBI chr 2:142,761,303...142,794,767
Ensembl chr 2:142,761,416...142,795,068
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions increases phosphorylation |
ISO |
ciglitazone promotes the reaction [Niflumic Acid results in increased phosphorylation of EIF2AK3 protein]; Niflumic Acid promotes the reaction [ciglitazone results in increased phosphorylation of EIF2AK3 protein] |
CTD |
PMID:21067863 |
|
NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911
|
|
G |
Faah |
fatty acid amide hydrolase |
decreases activity |
EXP |
Niflumic Acid results in decreased activity of FAAH protein |
CTD |
PMID:12751821 |
|
NCBI chr 5:129,479,774...129,499,018
Ensembl chr 5:129,479,824...129,498,677
|
|
G |
Gabra1 |
gamma-aminobutyric acid type A receptor subunit alpha 1 |
multiple interactions |
EXP |
Niflumic Acid promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]] |
CTD |
PMID:27720918 |
|
NCBI chr10:26,595,151...26,650,611
Ensembl chr10:26,595,160...26,650,864
|
|
G |
Gabra6 |
gamma-aminobutyric acid type A receptor subunit alpha6 |
multiple interactions |
EXP |
Niflumic Acid inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA6 protein binds to GABRB2 protein binds to GABRG2 protein]] |
CTD |
PMID:27720918 |
|
NCBI chr10:26,810,411...26,825,768
Ensembl chr10:26,810,423...26,825,769
|
|
G |
Gabrb2 |
gamma-aminobutyric acid type A receptor subunit beta 2 |
multiple interactions |
EXP |
Niflumic Acid inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA6 protein binds to GABRB2 protein binds to GABRG2 protein]]; Niflumic Acid promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]] |
CTD |
PMID:27720918 |
|
NCBI chr10:26,936,592...27,156,141
Ensembl chr10:26,936,551...27,151,251
|
|
G |
Gabrg2 |
gamma-aminobutyric acid type A receptor subunit gamma 2 |
multiple interactions |
EXP |
Niflumic Acid inhibits the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA6 protein binds to GABRB2 protein binds to GABRG2 protein]]; Niflumic Acid promotes the reaction [gamma-Aminobutyric Acid results in increased activity of [GABRA1 protein binds to GABRB2 protein binds to GABRG2 protein]] |
CTD |
PMID:27720918 |
|
NCBI chr10:26,374,693...26,463,937
Ensembl chr10:26,374,694...26,464,346
|
|
G |
Gpr35 |
G protein-coupled receptor 35 |
multiple interactions |
ISO |
Niflumic Acid binds to and results in increased activity of GPR35 protein |
CTD |
PMID:20919992 |
|
NCBI chr 9:93,527,165...93,539,573
Ensembl chr 9:93,527,127...93,539,299
|
|
G |
Hpgd |
15-hydroxyprostaglandin dehydrogenase |
multiple interactions |
ISO |
[Niflumic Acid co-treated with NAD] binds to HPGD protein |
CTD |
PMID:25526675 |
|
NCBI chr16:33,986,265...34,024,228
Ensembl chr16:33,986,266...34,024,228
|
|
G |
Hspa1b |
heat shock protein family A (Hsp70) member 1B |
affects expression |
ISO |
Niflumic Acid affects the expression of HSPA1B protein |
CTD |
PMID:16184763 |
|
NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240 Ensembl chr20:3,856,006...3,873,240
|
|
G |
Kcnh2 |
potassium voltage-gated channel subfamily H member 2 |
multiple interactions |
ISO |
E 4031 inhibits the reaction [Niflumic Acid promotes the reaction [KCNH2 protein results in increased transport of Potassium]]; Niflumic Acid promotes the reaction [KCNH2 protein results in increased transport of Potassium] |
CTD |
PMID:12359267 |
|
NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008
|
|
G |
Kcnk10 |
potassium two pore domain channel subfamily K member 10 |
multiple interactions |
ISO |
Niflumic Acid promotes the reaction [KCNK10 protein results in increased transport of Potassium] |
CTD |
PMID:16075240 |
|
NCBI chr 6:117,690,052...117,826,120
Ensembl chr 6:117,694,222...117,825,695
|
|
G |
Kcnk2 |
potassium two pore domain channel subfamily K member 2 |
multiple interactions |
ISO |
Niflumic Acid promotes the reaction [KCNK2 protein results in increased transport of Potassium] |
CTD |
PMID:16075240 |
|
NCBI chr13:100,766,101...100,963,435
Ensembl chr13:100,766,113...100,963,435
|
|
G |
Kcnk4 |
potassium two pore domain channel subfamily K member 4 |
multiple interactions |
ISO |
Niflumic Acid promotes the reaction [KCNK4 protein results in increased transport of Potassium] |
CTD |
PMID:16075240 |
|
NCBI chr 1:204,117,941...204,129,494
Ensembl chr 1:204,114,572...204,125,925
|
|
G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
multiple interactions |
ISO |
Niflumic Acid inhibits the reaction [Histamine results in increased expression of MUC5AC mRNA]; Niflumic Acid inhibits the reaction [Histamine results in increased expression of MUC5AC protein] |
CTD |
PMID:17622767 |
|
NCBI chr 1:196,864,336...196,896,475
Ensembl chr 1:196,864,336...196,896,475
|
|
G |
Nmral1 |
NmrA like redox sensor 1 |
multiple interactions |
ISO |
[Niflumic Acid co-treated with NADP] binds to NMRAL1 protein |
CTD |
PMID:25526675 |
|
NCBI chr10:10,841,693...10,850,199
Ensembl chr10:10,841,799...10,850,192
|
|
G |
Panx1 |
Pannexin 1 |
decreases activity |
ISO |
Niflumic Acid results in decreased activity of PANX1 protein |
CTD |
PMID:19023039 |
|
NCBI chr 8:11,851,176...11,889,774
Ensembl chr 8:11,850,730...11,889,774
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [ciglitazone promotes the reaction [Niflumic Acid results in increased cleavage of PARP1 protein]]; benzyloxycarbonyl-isoleucyl-glutamyl-threonyl-aspartic acid fluoromethyl ketone inhibits the reaction [Niflumic Acid promotes the reaction [ciglitazone results in increased cleavage of PARP1 protein]]; ciglitazone promotes the reaction [Niflumic Acid results in increased cleavage of PARP1 protein]; DDIT3 mutant form inhibits the reaction [ciglitazone promotes the reaction [Niflumic Acid results in increased cleavage of PARP1 protein]]; DDIT3 mutant form inhibits the reaction [Niflumic Acid promotes the reaction [ciglitazone results in increased cleavage of PARP1 protein]]; Niflumic Acid promotes the reaction [ciglitazone results in increased cleavage of PARP1 protein] |
CTD |
PMID:21067863 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
increases expression |
ISO |
Niflumic Acid results in increased expression of PPARG protein |
CTD |
PMID:21067863 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptgr1 |
prostaglandin reductase 1 |
decreases activity |
ISO |
Niflumic Acid results in decreased activity of PTGR1 protein |
CTD |
PMID:25619643 |
|
NCBI chr 5:73,784,000...73,802,624
Ensembl chr 5:73,784,009...73,802,666
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
ISO |
Niflumic Acid results in increased expression of PTGS2 protein PTGS2 inhibits the reaction [Niflumic Acid results in increased uptake of Hexoses] |
CTD |
PMID:16447059 PMID:21067863 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Slc2a1 |
solute carrier family 2 member 1 |
multiple interactions |
ISO |
SLC2A1 inhibits the reaction [Niflumic Acid results in increased uptake of Hexoses] |
CTD |
PMID:16447059 |
|
NCBI chr 5:132,717,196...132,745,416
Ensembl chr 5:132,717,196...132,745,416
|
|
G |
Slc2a4 |
solute carrier family 2 member 4 |
multiple interactions increases expression |
ISO |
[Niflumic Acid results in increased expression of SLC2A4 protein] which results in increased uptake of Hexoses Niflumic Acid results in increased expression of SLC2A4 mRNA; Niflumic Acid results in increased expression of SLC2A4 protein |
CTD |
PMID:16447059 |
|
NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565
|
|
G |
Slc4a1 |
solute carrier family 4 member 1 (Diego blood group) |
multiple interactions |
ISO |
Niflumic Acid inhibits the reaction [SLC4A1 protein results in increased transport of Chlorides] |
CTD |
PMID:2511191 |
|
NCBI chr10:87,306,865...87,323,132
Ensembl chr10:87,306,872...87,323,117
|
|
G |
Slc6a1 |
solute carrier family 6 member 1 |
multiple interactions |
ISO |
Niflumic Acid inhibits the reaction [SLC6A1 protein results in increased uptake of gamma-Aminobutyric Acid] |
CTD |
PMID:15981712 |
|
NCBI chr 4:147,448,961...147,482,295
Ensembl chr 4:147,466,965...147,482,293
|
|
G |
Slc6a11 |
solute carrier family 6 member 11 |
multiple interactions |
ISO |
Niflumic Acid inhibits the reaction [SLC6A11 protein results in increased uptake of gamma-Aminobutyric Acid] |
CTD |
PMID:15981712 |
|
NCBI chr 4:147,297,972...147,413,319
Ensembl chr 4:147,297,969...147,413,443
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
decreases activity |
ISO |
Niflumic Acid results in decreased activity of UGT1A1 protein |
CTD |
PMID:15593333 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
multiple interactions decreases activity |
ISO |
Niflumic Acid inhibits the reaction [UGT1A9 protein results in increased glucuronidation of 4-cresol] Niflumic Acid results in decreased activity of UGT1A9 protein |
CTD |
PMID:32421801 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|